Proinflammatory effects of photoactivated methylene blue on rat model of Walker 256 carcinosarcoma
DOI:
https://doi.org/10.32471/exp-oncology.2312-8852.vol-41-no-2.13047Keywords:
cancer, inflammation, methylene blue, photodynamic therapy, photosensitizing agent, Walker carcinosarcoma 256 cellsAbstract
Summary. Background. Photodynamic therapy (PDT) is an anticancer therapy that associates the photosensitizer (PS), oxygen and light to destroy cancer cells. Methylene blue (MB) is considered a second generation phenothiazine dye with excellent photochemical properties. Aim: To evaluate whether MB-mediated PDT can induce oxidative stress and inflammation, therefore, interfering tumor growth. Materials and Methods: The study was conducted on Wistar rats transplanted with Walker 256 carcinosarcoma (W256). The proinflammatory interleukins levels (IL-1β, IL-6, IL-10, TNF-α) were determined by ELISA, mRNA expression of COX-1, COX-2, iNOS and eNOS by RT-PCR, lipid peroxidation was measured by the TBARS method. Moreover, myeloperoxidase (MPO) activity in neutrophils was determined by MPO activity assay. All indices mentioned above were determined in tumor tissue. Kaplan — Meier and Gehan — Breslow — Wilcoxon tests were used for survival analysis. Results: We found that the treatment of W256 with 0.1% MB + 1 J/cm2 provoked a significant increase in the interleukins levels (IL-1β, IL-6, IL-10, TNF-α), prostaglandin E2, the mRNA expression of COX-2, iNOS, lipid peroxidation and MPO activity in tumor tissue, which were statistically different (p < 0.05) compared to other experimental and control groups. The results of the estimation of survival curves show a greater probability of survival in 0.1% MB + 1 J/cm2 (total energy dose =142.8 J/cm2) treated group. Conclusion: Our results suggest that treatment of W256 with 0.1% MB + 1 J/cm2 was able to promote cytotoxic effects in tumor tissue by the generation of reactive oxygen species causing inflammation and thus interfering in the tumor growth.
References
Anand S, Ortel BJ, Pereira SP, et al. Biomodulatory approaches to photodynamic therapy for solid tumors. Cancer Lett 2012; 326: 8–16.
Hasan T, Ortel B, Solban N, Pogue B. Photodynamic therapy of cancer. Cancer Medicine, 7th ed. Hamilton, Ontario: BC Decker Inc, 2006: 537–48.
Celli JP, Spring BQ, Rizvi I, et al. Imaging and photodynamic therapy: mechanisms, monitoring, and optimization. Chem Rev 2010; 110: 2795–838.
Buytaert E, Dewaele M, Agostinis P. Molecular effectors of multiple cell death pathways initiated by photodynamic therapy. Biochim Biophys Acta 2007; 1776: 86–107.
Garg AD, Nowis D, Golab J, Agostinis P. Photodynamic therapy: illuminating the road from cell death towards anti-tumour immunity. Apoptosis 2010; 15: 1050–71.
Pizova K, Tomankova K, Daskova A, et al. Photodynamic therapy for enhancing antitumour immunity. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2012; 156: 93–102.
Robertson CA, Evans DH, Abrahamse H. Photodynamic therapy (PDT): a short review on cellular mechanisms and cancer research applications for PDT. J Photochem Photobiol B 2009; 96: 1–8.
Agostinis P, Berg K, Cengel KA, et al. Photodynamic therapy of cancer: an update. CA Cancer J Clin 2011; 61: 250–81.
O’Connor AE, Gallagher WM, Byrne AT. Porphyrin and nonporphyrin photosensitizers in oncology: preclinical and clinical advances in photodynamic therapy. Photochem Photobiol 2009; 85: 1053–74.
García-Díaz M, Kawakubo M, Mroz P, et al. Cellular and vascular effects of the photodynamic agent temocene are modulated by the delivery vehicle. J Control Release 2012; 162: 355–63.
Krammer B. Vascular effects of photodynamic therapy. Anticancer Res 2001; 21: 4271–7.
Preise D, Scherz A, Salomon Y. Antitumor immunity promoted by vascular occluding therapy: lessons from vascular-targeted photodynamic therapy (VTP). Photochem Photobiol Sci 2011; 10: 681–8.
St Denis TG, Aziz K, Waheed AA, et al. Combination approaches to potentiate immune response after photodynamic therapy for cancer. Photochem Photobiol Sci 2011; 10: 792–801.
Korbelik M. Cancer vaccines generated by photodynamic therapy. Photochem Photobiol Sci 2011; 10: 664–9.
Bhuvaneswari R, Gan YY, Soo KC, Olivo M. The effect of photodynamic therapy on tumor angiogenesis. Cell Mol Life Sci 2009; 66: 2275–83.
Kwitniewski M, Juzeniene A, Glosnicka R, Moan J. Immunotherapy: a way to improve the therapeutic outcome of photodynamic therapy? Photochem Photobiol Sci 2008; 7: 1011–7.
Kousis PC, Henderson BW, Maier PG, Gollnick SO. Photodynamic therapy enhancement of antitumor immunity is regulated by neutrophils. Cancer Res 2007; 67: 10501–10.
Yang D, de la Rosa G, Tewary P, Oppenheim JJ. Alarmins link neutrophils and dendritic cells. Trends Immunol 2009; 30: 531–7.
Tracy EC, Bowman MJ, Henderson BW, Baumann H. Interleukin-1α is the major alarmin of lung epithelial cells released during photodynamic therapy to induce inflammatory mediators in fibroblasts. Br J Cancer 2012; 107: 1534–46.
Dobson J, de Queiroz GF, Golding JP. Photodynamic therapy and diagnosis: principles and comparative aspects. Vet J 2018; 233: 8–18.
Ginimuge PR, Jyothi SD. Methylene blue: revisited. J Anaesthesiol Clin Pharmacol 2010; 26: 517–20.
Jena S, Chainy GB. Effect of methylene blue on oxidative stress and antioxidant defence parameters of rat hepatic and renal tissues. Indian J Physiol Pharmacol 2008; 52: 293–6.
Schirmer RH, Adler H, Pickhardt M, Mandelkow E. Lest we forget you — methylene blue… Neurobiol Aging 2011; 32: 2325.e7–16.
Tardivo JP, Del Giglio A, de Oliveira CS, et al. Methylene blue in photodynamic therapy: From basic mechanisms to clinical applications. Photodiagnosis Photodyn Ther 2005; 2: 175–91.
Auerbach SS, Bristol DW, Peckham JC, et al. Toxicity and carcinogenicity studies of methylene blue. Food Chem Toxicol 2010; 48: 169–77.
Lu Y, Jiao R, Chen X, et al. Methylene blue-mediated photodynamic therapy induces mitochondria-dependent apoptosis in HeLa cell. J Cell Biochem 2008; 105: 1451–60.
Peloi LS, Soares RR, Biondo CE, et al. Photodynamic effect of light-emitting diode light on cell growth inhibition induced by methylene blue. J Biosci 2008; 33: 231–7.
Chen Y, Zheng W, Li Y, et al. Apoptosis induced by methylene-blue-mediated photodynamic therapy in melanomas and the involvement of mitochondrial dysfunction revealed by proteomics. Cancer Sci 2008; 99: 2019–27.
Wondrak GT. NQO1-activated phenothiazinium redox cyclers for the targeted bioreductive induction of cancer cell apoptosis. Free Radic Biol Med 2007; 43: 178–90.
Wu WS. The signaling mechanism of ROS in tumor progression. Cancer Metastasis Rev 2006; 25: 695–705.
Cen D, Brayton D, Shahandeh B, et al. Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells. J Med Chem 2004; 47: 6914–20.
Miller RA, Woodburn KW, Fan Q, et al. Motexafin gadolinium: a redox active drug that enhances the efficacy of bleomycin and doxorubicin. Clin Cancer Res 2001; 7: 3215–21.
Renschler MF. The emerging role of reactive oxygen species in cancer therapy. Eur J Cancer 2004; 40: 1934–40.
Fry FH, Holme AL, Giles NM, et al. Multifunctional redox catalysts as selective enhancers of oxidative stress. Org Biomol Chem 2005; 3: 2579–87.
Rugolo M, Lenaz G. Monitoring of the mitochondrial and plasma membrane potentials in human fibroblasts by tetraphenylphosphonium ion distribution. J Bioenerg Biomembr 1987; 19: 705–18.
Gabrielli D, Belisle E, Severino D, et al. Binding, aggregation and photochemical properties of methylene blue in mitochondrial suspensions. Photochem Photobiol 2004; 79: 227–32.
His RA, Rosenthal DI, Glatstein E. Photodynamic therapy in the treatment of cancer: current state of the art. Drugs 1999; 57: 725–34.
Moan J, Berg K. The photodegradation of porphyrins in cells can be used to estimate the lifetime of singlet oxygen. Photochem Photobiol 1991; 53: 549–53.
Firczuk M, Nowis D, Gołąb J. PDT-induced inflammatory and host responses. Photochem Photobiol Sci 2011; 10: 653–63.
Buytaert E, Dewaele M, Agostinis P. Molecular effectors of multiple cell death pathways initiated by photodynamic therapy. Biochim Biophys Acta 2007; 1776: 86–107.
Girotti AW. Photosensitized oxidation of membrane lipids: reaction pathways, cytotoxic effects, and cytoprotective mechanisms. J Photochem Photobiol B 2001; 63: 103–13.
Matroule JY, Volanti C, Piette J. NF-kappaB in photodynamic therapy: discrepancies of a master regulator. Photochem Photobiol 2006; 82: 1241–6.
Panzarini E, Inguscio V, Dini L. Immunogenic cell death: can it be exploited in PhotoDynamic Therapy for cancer? Biomed Res Int 2013; 2013: 482160.
Brodin NP, Guha C, Tomé WA. Photodynamic therapy and its role in combined modality anticancer treatment. Technol Cancer Res Treat 2015; 14: 355–68.
Lechner M, Lirk P, Rieder J. Inducible nitric oxide synthase (iNOS) in tumor biology: the two sides of the same coin. Semin Cancer Biol 2005; 15: 277–89.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
